BARCELONA, Spain (AP) — Raphinha was released by Brazil on Wednesday because of a thigh injury.
The forward was replaced during the 4-2 win over Australia on Tuesday, when he scored from a penalty kick.
The Brazilian Football Confederation said the Barcelona player underwent imaging tests that revealed a minor muscle edema on the back of his right thigh.
“As a precaution and to ensure a speedy recovery, the player will be released from the Brazilian national team," the confederation said. “No replacement player will be called up for the friendly match against India.”
Brazil will play at India on Saturday for its final match of the international break. It also drew with Australia 1-1 on Friday.
Raphinha is expected to undergo further tests in Spain, where he will continue his recovery process at his club.
He is off to a red-hot start to the season having scored 15 goals in 10 games for club and country.
See AP’s full soccer coverage here
Brazil's Raphinha scores from a penalty during their international friendly soccer match against Australia in Brisbane, Australia, on Tuesday, Sept. 29, 2026. (AP Photo/Tertius Pickard)
Brazil's Raphinha, right, connects with Australia's Harry Souttar while going for the ball during their international friendly soccer match in Brisbane, Australia, on Tuesday, Sept. 29, 2026. (AP Photo/Tertius Pickard)
Brazil's Raphinha, right, celebrates scoring from a penalty as Australia's Connor Metcalfe walks past during their international friendly soccer match in Brisbane, Australia, on Tuesday, Sept. 29, 2026. (AP Photo/Tertius Pickard)
GLASGOW, Scotland--(BUSINESS WIRE)--Sep 30, 2026--
Multiple myeloma, long considered incurable, now has a rigorous definition of cure. The announcement led the International Myeloma Society’s (IMS) 23rd Annual Meeting, attended by over 4,000 people from more than 79 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929235740/en/
Nikhil C. Munshi, MD, presented the definition developed by IMS and the International Myeloma Working Group. A patient may be considered cured after five years in complete remission without myeloma treatment, counted from when treatment ends. The criteria include at least four negative measurable residual disease (MRD) tests, including one at five years, sensitive enough to detect one myeloma cell in a million. Imaging must show no disease at the start and end.
“We are no longer debating whether cure is possible,” said Dr. Munshi, IMS’s immediate past president. “We are defining it rigorously, measuring it precisely, and expanding the number of patients who can achieve it.”
Breakthrough data presented at the meeting included:
Other sessions addressed blood-based monitoring, immune protection and the biology of high-risk disease. Bone marrow testing remains the standard for assessing residual disease.
IMS26 Abstracts Book: https://www.myelomasociety.org/publications/
On-demand meeting content: myelomasociety.org.
About the International Myeloma Society
The International Myeloma Society is the only global non-profit focused on myeloma research and clinical care. Representing thousands of experts across more than 75 countries, IMS accelerates cures, fosters collaboration, and transforms patient care. The organization emphasizes funding research (with $18.5 Million Provided) and advancing clinical care access in low-to-middle income countries.
Global Myeloma Experts Define Cure as New Approaches to Treatment Advance
